Last reviewed · How we verify

Edgar LeClaire, MD — Portfolio Competitive Intelligence Brief

Edgar LeClaire, MD pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Active B&O suppository of belladonna Active B&O suppository of belladonna marketed Anticholinergic agent Muscarinic acetylcholine receptors (M1-M5) Gastroenterology
Onabotulinumtoxin A (BoNT) Onabotulinumtoxin A (BoNT) marketed Neurotoxin; botulinum toxin serotype A SNAP-25 (synaptosome-associated protein of 25 kDa) Neurology; Dermatology; Aesthetics

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Alza Corporation, DE, USA · 1 shared drug class
  2. GlaxoSmithKline · 1 shared drug class
  3. Janssen-Cilag Ltd.,Thailand · 1 shared drug class
  4. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 shared drug class
  5. Repurposed Therapeutics, Inc. · 1 shared drug class
  6. Rutgers, The State University of New Jersey · 1 shared drug class
  7. Stony Brook University · 1 shared drug class
  8. Toronto Rehabilitation Institute · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Edgar LeClaire, MD:

Cite this brief

Drug Landscape (2026). Edgar LeClaire, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/edgar-leclaire-md. Accessed 2026-05-16.

Related